购物车
- 全部删除
- 您的购物车当前为空
CFT8634 是一种具有口服活性和选择的降解剂,靶向 BRD9,对SMARCB1缺陷型癌细胞系的增殖有影响。CFT8634 可诱导与 BRD9 和 E3 连接酶形成三元复合物,诱导 BRD9 泛素化并随后被蛋白酶体降解。
CFT8634 是一种具有口服活性和选择的降解剂,靶向 BRD9,对SMARCB1缺陷型癌细胞系的增殖有影响。CFT8634 可诱导与 BRD9 和 E3 连接酶形成三元复合物,诱导 BRD9 泛素化并随后被蛋白酶体降解。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 2,470 | 10-14周 | |
5 mg | ¥ 5,890 | 10-14周 | |
10 mg | ¥ 7,930 | 10-14周 | |
25 mg | ¥ 11,800 | 10-14周 | |
50 mg | ¥ 16,200 | 10-14周 | |
100 mg | ¥ 21,900 | 10-14周 |
产品描述 | CFT8634 is an orally active and selective degrader targeting BRD9, with effects on the proliferation of SMARCB1-deficient cancer cell lines. CFT8634 induces the formation of a ternary complex with BRD9 and E3 ligase, inducing BRD9 ubiquitination and subsequent degradation by the proteasome. |
分子量 | 710.79 |
分子式 | C37H45F3N6O5 |
CAS No. | 2704617-96-7 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 100 mg/mL (140.69 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容